Panelists from Genovac, will present case studies of how they have leveraged their core genetic immunization technology and the Beacon optofluidic system to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.
Discover how the Beacon system shortens timelines, simplifies workflows and reveals detailed data through deep profiling.
Watch our presentation at AE&T Digital Week, hosted with Genovac, to hear how the Beacon system is making it possible to find 10 times more lead candidates than hybridoma in just days.
At the 2021 AE&T EU conference, Tracey Mullens, CEO of Abveris, and Brian Walters, CEO of Genovac, joined John Proctor, SVP Antibody Therapeutics, for a discussion about the evolving landscape of antibody therapeutics, the technologies they have turned to address today’s complex targets, and how they are preparing for tomorrow’s challenges.